|
|
|
|
If you are having trouble viewing this email, please view it in your browser. |
|
|
|
|
 |
|
|
|
|
|
|
Marinova Newsletter |
|
|
June 2016 |
|
|
|
|
|
|
|
Welcome from Paul Garrott, CEO
There has been considerable media attention recently on the prevalence of inferior nutritional supplements and the risks that these may pose to the health of consumers. This publicity has largely been focussed on the extent of sub-standard nutritional products in the USA and – whilst it is comforting to know that Australia boasts a well-regulated system for dietary supplements – consumers are now living in a world where purchasing from overseas is just a click away. In this newsletter, we look at the key challenges confronting manufacturers and consumers of nutraceutical products and the importance of effective quality control at every stage of the supply chain.
Also featured in this edition is the latest fucoidan biomaterial innovation from RMIT University in Australia and its potential in cancer treatment. We also announce the signing of a new research agreement with the University of Tasmania and highlight recent research findings on the bioactivity of fucoidan.
I would like to thank you for your support and interest in Marinova and we hope you enjoy reading this latest edition of our news. As always, we welcome any suggestions or feedback.
|
|
|
In this issue
Quick links
|
|
|
|
|
|
|
|
|
|
|
|
|
Innovative fucoidan biomaterial combats cancer
|
|
|
Researchers at RMIT University in Melbourne, Australia, have successfully created a new biomaterial nanoscaffold designed to address cancer, using Maritech® fucoidan. Epithelial cancers (such as oral cancer) can be particularly aggressive and difficult to treat, making this innovation highly appealing within the medical field. READ MORE >
|
|
|
|
|
Fucoidan in the headlines |
|
|
|
Fucoidan protects against pollution damage
|
|
 |
|
The WHO classified diesel exhaust fumes as a carcinogen in 2012, with exposure being a major risk factor for lung cancer and cardiopulmonary disease. A recent study has demonstrated that fucoidan prevents decreased function of cultured epithelial cells following their exposure to diesel exhaust particles, by reducing oxidative stress and protecting cell permeability. This study provides further evidence that fucoidan may protect against damage caused by pollution exposure. FULL ARTICLE >
|
|
Fucoidan improves serum lipid levels
|
|
 |
|
Diets high in fats are known to cause health implications, and yet western diets often exceed the recommended limits for fat intake. Korean researchers have now shown that ingestion of fucoidan is highly effective in lowering blood lipid levels in a model of hyperlipidemia. They established that the mechanism was due to fucoidan regulating the function of key enzymes in the liver, which control cholesterol and triglyceride synthesis.
FULL ARTICLE >
|
|
Fucoidan reduces colitis symptoms
|
|
 |
|
Following on from recent research undertaken on Maritech® fucoidan, researchers have provided further confirmation of the anti-colitis benefits of fucoidan. Fucoidan-fed pigs with induced colitis showed a decrease in pathology and cytokine expression. Overall, the inclusion of fucoidan in the diet improved body weight, diarrhoeal scores and clinical variables associated with the colitis model. It also reduced key colonic inflammatory markers. FULL ARTICLE >
|
|
|
|
|
|
Marinova extends research alliance |
|
Marinova is very pleased to announce the signing of another agreement with the University of Tasmania, to further explore the anti-inflammatory effects of Maritech® fucoidan extracts. This new research agreement is the latest in a series of collaborative projects that Marinova is undertaking with the Faculty of Health at the University of Tasmania. Associate Professor Nuri Güven from the University’s School of Medicine will supervise the new multi-faceted project... READ MORE >
|
|
|
|
|
|
|
Safety and regulation of supplements |
|
|
|
|
The use and acceptance of complementary medicine continues to grow exponentially across the globe, with approximately 4 billion people (80% of the worldwide population) currently relying on medicinal herbal products.
Recent investigations however have highlighted the prevalence of substandard natural therapies entering the market, particularly in the USA. Research from Guelph University showed nearly 60% of 44 supplements... READ MORE >
|
|
|
|
|
Staff profile: Ms Krutika Sen |
|
Marinova wishes to introduce its new Scientific and Technical Support Officer, Ms Krutika Sen.
Krutika joined Marinova in February 2016 after completing her Masters of Biotechnology at Deakin University and Masters in Business Administration at the University of Tasmania.
Click here to learn more about Krutika in a brief personal interview.
|
|
|
|
|
|
|
Marinova supports first ANZ-MBS Symposium |
|
|
|
|
Marinova was pleased to support the inaugural Australia New Zealand Marine Biotechnology Society (ANZ-MBS) Symposium in Adelaide earlier this year, through representation by Chief Scientist, Dr Helen Fitton, and Operations Manager, Dr Damien Stringer.
In her Plenary Address, Dr Fitton addressed the importance of sustainable, effective marine biotechnology in solving many of today’s problems. “The extensive and unique... READ MORE >
|
|
|
Meet Marinova: Upcoming events in 2016
|
|
|
|
|
|
|
 |
|
22nd International Seaweed Symposium
Meet: Mr Paul Garrott (CEO & Managing Director) and
Dr Damien Stringer (Operations Manager)
Presenting: Fucoidan and cancer: research and clinical interaction studies (Dr Damien Stringer)
When: 19th - 24th June 2016
Where: Scandic Hotel, Copenhagen, Denmark
|
|
|
|
|
 |
|
Cross Pollinate Conference
Meet: Ms Tess Oddie (Marketing & Communications Officer)
When: 21st - 22nd August, 2016
Where: MONA, Tasmania, Australia
|
|
|
|
|
|
|
|
|
Not interested anymore? Unsubscribe. |
|
|
|
|
